tahseentbrcOct 13

🌍 Zynteglo Market Outlook 2025: Global Gene Therapy Growth & Future Trends

It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.

Read More @ https://goodprnews.com/zynteglo-market-growth/

#marketresearchreport #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #Zynteglo

Zynteglo Market Growth Outlook: Key Drivers and Emerging Opportunities (2025-2034) - Good PR News

What are the latest figures on the zynteglo market’s size and projected CAGR? The zynteglo market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to

Good PR News - Global Free Press Release Submissions Site
Show threadBrittany TrangDec 13, 2023

I thought that the fantastical price tag might be keeping some patients from getting #Zynteglo

Turns out, that doesn't seem to be the case (yet), as I detail in a sister piece about Bluebird and the #insurance logistics behind these therapies:

https://www.statnews.com/2023/12/08/lyfgenia-sickle-cell-gene-therapy-bluebird-vertex-crispr-casgevy/

#health #healthcare #scd #crispr #betathalassemia #transplant #lyfgenia #casgevy #healthinsurance #pharma #bigpharma #biotech

Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy

The FDA's approval of two gene therapies sets the stage for intense competition between Bluebird Bio and the partnership of Vertex and CRISPR Therapeutics.

STAT
Show threadBrittany TrangDec 13, 2023

I've been working on this story in some fashion since my first week at @STAT last Aug. The approval of Bluebird Bio's #genetherapy #Zynteglo for beta thalassemia caught my attention because

1) I myself carry the beta thal gene
2) The treatment is $2.8 million, at that time the most expensive drug ever

#drugprices #health #healthcare #scd #crispr #betathalassemia #transplant

Show threadBrittany TrangDec 8, 2023

Don't miss the rest of STAT's coverage of this historic moment:
https://www.statnews.com/2023/12/08/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease/

#health #healthcare #medicine #biotech #pharma #crispr #genetherapy #geneediting #scd #SickleCell #casgevy #lyfgenia #zynteglo

In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

The FDA has approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease.

STAT
Brittany TrangDec 8, 2023

Today the FDA approved 2 gene therapies to treat sickle cell disease, including the first CRISPR-based therapy.

Bluebird Bio, who has the ~$1M more expensive and not-CRISPR therapy, has a single card left to play in this competition: It's been conducting a year-long dress rehearsal for this moment

https://www.statnews.com/2023/12/08/lyfgenia-sickle-cell-gene-therapy-bluebird-vertex-crispr-casgevy/

#health #healthcare #medicine #biotech #pharma #crispr #genetherapy #geneediting #scd #SickleCell #casgevy #lyfgenia #zynteglo

Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy

The FDA's approval of two gene therapies sets the stage for intense competition between Bluebird Bio and the partnership of Vertex and CRISPR Therapeutics.

STAT